Dapagliflozin Safe, Effective in Advanced Chronic Kidney Disease
Dapagliflozin’s benefits among patients with stage 4 CKD were consistent with those observed in the larger DAPA-CKD cohort with stage 2-3 CKD.
Diabetic Nephropathy
High iPTH Linked With Cardiovascular Outcomes in Diabetic Kidney Disease
Study findings indicate a correlation between iPTH and vascular calcification in patients with diabetic kidney disease.
Kerendia Approved to Reduce CKD Progression, CV Risk in Patients With Diabetic Kidney Disease
The approval was based on data from the phase 3 FIDELIO-DKD trial.
Efpeglenatide Improves Renal, Cardiovascular Outcomes in High-Risk Diabetes
Among the patients with high-risk diabetes in the trial, 21.8% had both a history of cardiovascular disease and current kidney disease.
Four in 10 Diabetes Patients Have Kidney Disease
More than one-quarter are classified as rapid decliners, which was more common with type 2 diabetes
Finerenone Reduces New-Onset AF in Patients With CKD and T2D
Because finerenone inhibits cardiac remodeling in preclinical models, investigators sought to examine its effect on new-onset AFF by analyzing data from the FIDELIO-DKD phase 3 trial.
IL-6 Levels Linked With Progression of Diabetic Kidney Disease
In a small trial, patients with the highest tertile of IL-6 experienced significantly faster progression of diabetic kidney disease.
Renoprotective Effect of SGLT2 Inhibitors Mediated Largely by Hematocrit
Increases in the proportion of red blood cells mediates the reduction in renal risks associated with SGLT2 inhibitor therapy in patients with type 2 diabetes and cardiovascular disease, a study found.
Semaglutide Effective in High-Risk Diabetic Kidney Disease
More than two-thirds of patients experienced a more than 5% weight loss with 12 months of etelcalcetide treatment.
Study: Etelcalcetide Can Be Used Safely in Diabetic Nephropathy
Etelcalcetide use in patients with diabetic nephropathy might protect against development of adynamic bone disease, according to investigators.
- Loading...
Loading...
Next post in Secondary Hyperparathyroidism
Loading... 
Loading...